This paper is in the following e-collection/theme issue:

mHealth for Rehabilitation (236) Cardiac Rehabilitation (81) mHealth for Symptom and Disease Monitoring, Chronic Disease Management (1317) mHealth for Treatment Adherence (386) Coronary Heart Disease (74) Mobile Health (mhealth) (2777)

Published on in Vol 12 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/55421, first published .
Efficacy of a Mobile Health App (eMOTIVA) Regarding Compliance With Cardiac Rehabilitation Guidelines in Patients With Coronary Artery Disease: Randomized Controlled Clinical Trial

Efficacy of a Mobile Health App (eMOTIVA) Regarding Compliance With Cardiac Rehabilitation Guidelines in Patients With Coronary Artery Disease: Randomized Controlled Clinical Trial

Efficacy of a Mobile Health App (eMOTIVA) Regarding Compliance With Cardiac Rehabilitation Guidelines in Patients With Coronary Artery Disease: Randomized Controlled Clinical Trial

Authors of this article:

Celia Cruz-Cobo1, 2, 3 Author Orcid Image ;   María Ángeles Bernal-Jiménez1, 2, 3 Author Orcid Image ;   Germán Calle2, 4 Author Orcid Image ;   Livia Luciana Gheorghe2, 4 Author Orcid Image ;   Alejandro Gutiérrez-Barrios2, 4 Author Orcid Image ;   Dolores Cañadas2, 4 Author Orcid Image ;   Josep A Tur5 Author Orcid Image ;   Rafael Vázquez-García2, 4 Author Orcid Image ;   María José Santi-Cano1, 2, 3 Author Orcid Image
Article Authors Cited by Tweetations Metrics

    Original Paper

    1Faculty of Nursing and Physiotherapy, University of Cádiz, Cádiz, Spain

    2Institute of Biomedical Research and Innovation of Cádiz, Cádiz, Spain

    3Research Group on Nutrition, Molecular, Pathophysiological and Social Issues, University of Cádiz, Cádiz, Spain

    4Cardiology Clinical Unit, Puerta del Mar Hospital, Cádiz, Spain

    5Research Group on Community Nutrition & Oxidative Stress, University of the Balearic Islands, Palma de Mallorca, Spain

    Corresponding Author:

    María Ángeles Bernal-Jiménez, RNC, PhD

    Faculty of Nursing and Physiotherapy

    University of Cádiz

    Avda. Ana de Viya, 52

    Cádiz, 11009

    Spain

    Phone: 34 956 019042

    Email: mariangeles.bernal@uca.es


    Background: Cardiac rehabilitation is fundamental among patients recovering from a coronary event, and mHealth technology may constitute a useful tool that provides guidelines based on scientific evidence in an entertaining, attractive, and user-friendly format.

    Objective: This study aimed to compare the efficacy of an mHealth intervention involving the eMOTIVA app and that of usual care regarding compliance with cardiac rehabilitation guidelines in terms of lifestyle, cardiovascular risk factors, and satisfaction among patients with acute coronary syndrome.

    Methods: A randomized controlled clinical trial with a parallel group design was conducted. It included 300 patients (mHealth group, 150; control group, 150) who underwent percutaneous coronary intervention for acute coronary syndrome. Both groups underwent evaluations initially (during hospitalization) and after 3 and 6 months (face-to-face consultations). The eMOTIVA app incorporates a virtual classroom providing audio and video information about a healthy lifestyle, a section for self-recording cardiovascular risk factors, and a section for feedback messages and gamification. The primary outcome variables were (1) adherence to the Mediterranean diet and the frequency of consumption of food; (2) physical activity level, sedentary time, and exercise capacity; (3) smoking cessation and nicotine dependence; (4) level of knowledge about cardiovascular risk factors; and (5) app satisfaction and usability.

    Results: The study analyzed 287 patients (mHealth group, 145; control group, 142). Most participants were male (207/300, 69.0%), and the mean age was 62.53 (SD 8.65) years. Significant improvements were observed in the mHealth group compared with the control group at 6 months in terms of (1) adherence to the Mediterranean diet (mean 11.92, SD 1.70 vs 8.92, SD 2.66 points; P<.001) and frequency of eating foods (red meat [≤1/week]: 141/143, 97.9% vs 96/141, 68.1%; industrial pastries [<2/week]: 129/143, 89.6% vs 80/141, 56.8%; oily fish [≥2/week]: 124/143, 86.1% vs 64/141, 41.4%; vegetables [≥2/day]: 130/143, 90.3% vs 78/141, 55.3%; fruit [≥2/day]: 128/143, 88.9% vs 85/141, 60.2%; all P<.001); (2) physical activity (mean 2112.66, SD 1196.67 vs 1372.60, SD 944.62 metabolic equivalents/week; P<.001) and sedentary time (mean 8.38, SD 1.88 vs 9.59, SD 2.09 hours; P<.001); (3) exercise capacity (distance: mean 473.49, SD 102.28 vs 447.25, SD 93.68 meters; P=.04); and (4) level of knowledge (mean 117.85, SD 3.83 vs 111.00, SD 7.11 points; P<.001). App satisfaction was high (mean 42.53, SD 6.38 points), and its usability was excellent (mean 95.60, SD 4.03 points).

    Conclusions: With the eMOTIVA app, favorable results were obtained in the intervention group in terms of adherence to the Mediterranean diet, frequency of eating certain foods, physical activity, sedentary time, exercise capacity, knowledge level, systolic blood pressure, heart rate, and blood sugar level. Furthermore, participants reported high app satisfaction and rated its usability as excellent. Thus, this innovative tool is very promising.

    Trial Registration: ClinicalTrials.gov NCT05247606; https://clinicaltrials.gov/study/NCT05247606

    JMIR Mhealth Uhealth 2024;12:e55421

    doi:10.2196/55421

    Keywords

    coronary event; coronary heart disease; eHealth; lifestyle; mHealth; mobile health 


    Cardiovascular disease remains the main cause of death worldwide and is responsible for 17.9 million fatalities every year [1]. In Europe, about 4 million deaths occur each year due to cardiovascular diseases. Although significant progress has been made in the diagnosis and treatment of acute coronary syndrome (ACS), nearly half of these deaths are due to ischemic heart disease [2,3]. In Spain, coronary heart disease (mainly acute myocardial infarction [AMI]) remains the leading cause of death, causing 29,068 deaths per year. Thus, reducing the prevalence of ACS is a crucial objective of public health [4,5].

    A large amount of evidence has shown that leading a healthy lifestyle and modifying cardiovascular risk factors (CVRFs), such as stopping smoking, consuming a healthy diet, losing weight, achieving a suitable level of physical activity (PA), and adhering to medication, are vital in the prevention of major adverse cardiac and cerebrovascular events and death in people with coronary artery disease (CAD) [6]. However, a third of patients with CAD do not follow advice about eating healthy, doing PA, and stopping smoking [7].

    Owing to medical advances, the mean hospital stay of patients after percutaneous coronary intervention (PCI) has decreased greatly in recent years, meaning that less time is available for providing health care education. Health education plays a fundamental role in the process of cardiac rehabilitation (CR) following ACS, as it empowers patients to take control of their health, improve treatment adherence, prevent future cardiovascular events, and enhance their overall quality of life [8,9]. Providing patients with ongoing support after their hospital discharge may be important after ACS. This should include changes in lifestyle, adherence to medication, and psychosocial well-being [10]. Secondary prevention, which focuses on reducing the risk of recurrent cardiovascular events in individuals who have already experienced ACS, plays a crucial role in the comprehensive management and ongoing care of these patients. CR after AMI is of utmost importance for several reasons. It reduces the risk of experiencing another cardiovascular event. Moreover, CR improves cardiovascular health through a structured program of physical exercise, health education, dietary advice, and emotional support designed to improve the quality of life of people who have experienced ACS. These programs help to control blood pressure, reduce stress, and promote healthy lifestyle habits, which contribute to better cardiovascular health. These programs also contribute to functional recovery. After AMI, many people may experience limitations in their physical and functional abilities. CR can help regain muscle strength, endurance, and cardiac function, allowing patients to return to daily activities and work. Psychosocial support is also critical. CR offers emotional and psychological support, which can be instrumental in helping patients cope with anxiety, depression, and stress closely related to coronary heart disease [11]. However, despite its benefits, less than 50% of patients with coronary heart disease who are eligible for a CR program participate in CR after an acute coronary event. This may be due to limited accessibility and availability owing to a lack of facilities and long waiting lists. Patients may also experience logistical and transport barriers that make regular participation in face-to-face CR sessions difficult [12]. The widespread use of information and communication technology via smartphones may make it easier for health care professionals to handle these patients. Mobile health (mHealth) technology can provide evidence-based health care advice in an entertaining, attractive, and user-friendly format, thereby reducing the cost of health care [13]. In some cases, it may be a viable alternative or complementary approach to conventional CR. This modality involves participation in distance rehabilitation programs that encompass essential elements such as remote counseling, social interaction, supervision, and distance education [14].

    A recent meta-analysis [15] concluded that mHealth technology has a positive effect on patients who have experienced a coronary event. It analyzed the effectiveness of different kinds of mHealth programs in changing lifestyle, promoting treatment compliance, and controlling modifiable CVRFs. The analysis found improvements in exercise capacity, PA, physical and mental quality of life, and medication adherence. In addition, readmissions for all causes and cardiovascular causes were lower, although no significant improvements were found regarding blood lipids, arterial blood pressure, BMI, and waist circumference (WC). Another meta-analysis analyzed the effects of mHealth interventions on the risk factors of coronary heart disease, showing that they can lead to significant improvements in BMI, WC, blood lipids, diastolic blood pressure (DBP), and levels of depression. However, no improvements were found in systolic blood pressure (SBP) and anxiety [16].

    This clinical trial aimed to assess the efficacy of an mHealth intervention based on a mobile phone health (eMOTIVA) app compared with usual care for improving compliance with CR guidelines and evaluate the secondary prevention outcomes in patients who have experienced ACS. The following variables were assessed: improvements in lifestyle (adherence to the Mediterranean diet, frequency of foods consumed, PA, exercise capacity, sedentary time, smoking cessation, and level of knowledge); control of CVRFs, such as BMI, WC, blood pressure, heart rate (HR), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, blood sugar, and HbA1c; and usability and satisfaction with the app.


    Study Design

    We conducted a randomized controlled clinical trial with a parallel group design that included 300 patients with CAD who underwent PCI with stent implantation after ACS. The trial was conducted in the Cardiology Service of a public reference hospital in the south of Spain, in which 1500 PCIs are conducted every year.

    The trial has been developed and reported in agreement with the CONSORT (Consolidated Standards for Reporting Clinical Trials) checklist (Multimedia Appendix 1) [17]. The trial was registered at ClinicalTrials.gov (NCT05247606). The study protocol has been previously published [18].

    Participants

    During hospitalization, patients were considered eligible to participate if they had experienced myocardial infarction or angina and undergone revascularization with stent implantation, were younger than 75 years, had a smartphone or tablet with internet access for the duration of the study, and were able to manage the software. Patients were excluded if they had an expected survival of less than 1 year, had a physical disability, had severe heart failure, had a severe psychiatric illness, had dementia, did not speak Spanish, had a congenital heart disease with a rheumatic etiology, or required triple heart bypass surgery.

    A total of 150 patients were included in each arm. This sample size was considered sufficient to detect a mean effect size (Cohen d) of 0.5 [19] with regard to adherence to the Mediterranean diet (mean 8.6, SD 2.0 points) [20], adherence to PA (mean 210.2, SD 221.8 metabolic equivalent (MET)-min/week) [21,22], and a 12% decrease in the prevalence of smokers (prevalence of 21% from the prior pilot study), with a 95% confidence level and a statistical power of 80%.

    Recruitment, Randomization, and Blinding

    Recruitment took place between February 2022 and February 2023, and the follow-up continued until September 2023. The flow diagram of participants is shown in Figure 1.

    Participants meeting the inclusion criteria described above were randomly allocated using a computerized random number generator (1:1) to either the mHealth or control group (usual care). The researchers analyzing the results were blinded to the allocation of the participants.

    ‎
    Figure 1. Flow diagram. 6-MWT: 6-minute walk test; AMI: acute myocardial infarction; CVRF: cardiovascular risk factor; PCI: percutaneous coronary intervention.

    Intervention

    The intervention began while the patient was in the hospital after the coronary event. All participants in the mHealth group had the eMOTIVA app installed on their mobile phones or tablets. The app incorporates a virtual classroom that comprises a space for participation that guides the user using information based on scientific evidence to reach the treatment goals recommended in the clinical practice guidelines and to maintain a healthy lifestyle. This section addresses four cornerstones of the secondary prevention of cardiovascular diseases: (1) healthy lifestyle habits (diet, PA, and recommendations); (2) risk factors (high blood pressure, cholesterol, obesity, diabetes, tobacco use, and stress/anxiety); (3) compliance with the treatment; and (4) goals to be reached regarding diet, PA, body weight, blood pressure, blood sugar, smoking, and treatment. Each section includes online interactive videos (about indoor and outdoor PA, the correct self-measurement of blood pressure and WC, the treatment of cardiac events, and a guided mindfulness relaxation audio). In addition, the classroom provides documents that can be downloaded and printed such as weekly menus and graphics with information (food pyramid, heart health, characteristics and benefits of physical exercise, and recommendations for a healthy lifestyle to stop smoking and control stress). Each section includes a questionnaire that needs to be completed to obtain feedback about the knowledge acquired in the educational sessions. The app includes the use of behavioral strategies to achieve changes in habits through the self-recording of data in the sections related to food consumption, weekly body weight, treatment compliance, PA, smoking, and capillary blood sugar in patients with diabetes. To motivate the participants to improve and maintain healthy habits, the app includes some functions. First, reminders about healthy habits are generated at random on a pop-up screen once a week. Second, personalized messages are provided according to the user’s achievements, and recommendations are adapted to aspects that need to be improved, using information recorded during the previous week. These messages may be green (goal reached), yellow (goal partially reached), or red (goal still to be reached). Furthermore, each icon on the home page of the app appears in the colors according to the goals reached and aspects that need to be improved (Figure 2).

    The app uses gamification in the form of achievement icons. Users can obtain different medals if they meet the established recommendations for diet and PA during the months in which they use the app. These systems with fun rewards, such as digital badges obtained for specific objectives, are related to the participation and motivation of users in mHealth interventions, and they encourage an initial and sustained commitment among users to modify CVRFs [23,24]. In addition, gamification can make the intervention more enjoyable, and this is in line with the theory of self-reliance, which assumes that a key part of intrinsic motivation is enjoyment [25]. The app also has fun and colorful warnings and messages, advice, feedback, and self-comparisons through graphics detailing weekly progress (Figure 2).

    The app has a messaging section through which the patient can contact health care professionals and resolve any queries (Figure 2). The patients from both groups were evaluated through face-to-face consultations and assessments of medical records at the start and then 3 and 6 months after hospital discharge.

    ‎
    Figure 2. Contents of the eMOTIVA app.

    Outcome Variables

    The primary outcome measures at the end of the intervention in both groups were changes in behavior regarding (1) healthy diet (adherence to the Mediterranean diet and frequency of eating each food group); (2) level of PA (METs/week and min/week), sedentary time (hours sitting/week), and exercise capacity (6-minute walk test [6-MWT]); (3) smoking cessation in smokers and nicotine dependence; (4) level of knowledge acquired about CVRFs; and (5) app satisfaction and usability.

    The secondary outcome measures were (1) BMI and WC; (2) arterial blood pressure and HR; (3) TC, LDL-C, and triglycerides; and (4) HbA1c and blood sugar in patients with diabetes.

    Primary Outcomes

    Adherence to the Mediterranean diet questionnaire was used (total score: 14 points; <9 points: low adherence, ≥9 points: good adherence) to evaluate diet [20]. The frequency with which each food group was consumed was measured using a food consumption frequency questionnaire (for each food, the participant was required to tick the box indicating the mean frequency of consumption during the last week) [26]. PA time (min/week), intensity (METs/week), and sedentary time (hours seated/week) were analyzed using the International Physical Activity Questionnaire (IPAQ) [27] (light PA: minimum recommended walking of 150 min/week or 495 METs/week, moderate PA: minimum 600 METs/week, and vigorous PA: at least 3000 METs/week). Exercise capacity was measured with the 6-MWT (meters) [28]. Healthy people can walk between 400 and 700 meters in 6 minutes, depending on their age, height, and sex. A greater distance covered is associated with a higher exercise capacity. To this end, a change of 50 meters was established as a clinically significant improvement. A distance below 350 meters is considered a predictor of higher mortality in patients with chronic diseases [29,30]. Smoking cessation was self-reported and nicotine dependence was assessed using the Fagerström test (<4 points: low dependence, 4-7 points: moderate dependence, and 8-10 points: high dependence) [31]. Level of knowledge of CVRFs and a healthy lifestyle were analyzed using a scale validated by the research team in these kinds of patients (maximum score: 120 points). The scale comprises 24 items, each with a score between 1 and 5 points, and respondents were considered to have a high level of knowledge when the correct response was chosen for over 75% of the items (90 points) [32].

    Secondary Outcomes

    During hospital admission and in the physical follow-up visits, the following measurements were taken: body weight and height to calculate BMI, WC, SBP and DBP, HR, lipid values (TC, HDL-C, LDL-C, and triglycerides), HbA1c, and blood sugar.

    Finally, satisfaction with the app was assessed using a specific questionnaire developed by the research team (maximum score: 50 points; a higher score indicates more satisfaction), and the usability of the app was measured using the System Usability Scale (SUS) questionnaire (total score: 100 points; excellent: >80.3 points, good: 68-80.3 points, poor: 51-67 points, and very poor: <51 points) [33].

    Statistical Analysis

    A descriptive statistical analysis was performed. Continuous variables have been summarized as mean (SD), median, SD, 95% CI, and interquartile interval, depending on the distribution of the values (normal or nonnormal), and categorical variables have been summarized as frequency and percentage. At the end of the 6-month follow-up period, the means of the quantitative primary outcomes of the 2 groups (mHealth and control) were compared using the Student t-test (variables with normal distribution) and the Mann-Whitney U test (variables with nonnormal distribution). The chi-square or Fisher test was used for the comparison of the proportions of qualitative variables between the 2 groups (mHealth and control). A 2-tailed P-value of <.05 was considered statistically significant in all tests. SPSS version 24.0 (IBM Corp) was used for the analyses. The researchers analyzing the results were blinded to the allocation of the participants to each group.

    Ethical Considerations

    The project was approved by the Costa del Sol Research Ethics Committee, Ministry of Health and Families, Junta de Andalucía and was authorized by the hospital (approval number: 002_jun20_PI-RECAMAR-190. The study complies with Law 14/2007 on Biomedical Research and with the General European Data Protection Regulations, and was conducted following the standards and criteria set out in the latest version of the Helsinki Declaration issued in Fortaleza (Brazil) in October 2013. Moreover, all participants gave their written informed consent to participate in the study.

    Concerning the privacy and security of the app, each participant had a private username and password to access the app. Data were stored on a web server and not on a local computer. This web server works with anonymous data and is in Spain to comply with the regulations for the protection of high-level data. The web server performs daily backups of all files, and backups are performed by the software on demand. Thus, the data and program are protected.


    Overview

    During the recruitment period (February 2022 to February 2023), 986 patients underwent PCI and were evaluated for inclusion in the study. Among the patients evaluated, 668 were excluded for not fulfilling the inclusion and exclusion criteria, and 18 refused to participate. In the end, 300 patients were randomized into either the mHealth or control group (150 in each group). There were 9 dropouts in the control group (8 after 3 months and 1 after 6 months). In the mHealth group, there were 7 dropouts (5 after 3 months and 2 after 6 months) (Figure 1).

    The baseline characteristics of the participants are shown in Table 1. Most of the participants were male (207/300, 69.0%), and the mean age was 62.53 (SD 8.65) years. In general, both groups were homogeneous.

    Table 1. Patient baseline characteristics.
    CharacteristicTotal (N=300)mHealtha (n=150)Control (n=150)P value
    Male sex, n (%)207 (69.0)103 (68.7)104 (69.3).90
    Age (years).005

    		Mean (SD)62.53 (8.65)61.13 (8.69)63.93 (8.41)

    		95% CI61.55-63.5159.73-62.5462.57-65.28
    Educational level, n (%).11

    		Primary128 (44.9)59 (40.7)69 (49.3)

    		Middle school117 (41.1)60 (41.4)57 (40.7)

    		High school40 (14.0)26 (17.9)14 (10.0)
    Employment status, n (%).15

    		Employed94 (32.1)55 (37.2)39 (26.9)

    		Unemployed34 (11.6)19 (12.8)15 (10.3)

    		Retired149 (50.9)68 (45.9)81 (55.9)

    		Occupational disability16 (5.5)6 (4.1)10 (6.9)
    BMI (kg/m2).72

    		Mean (SD)28.75 (4.63)28.84 (4.56)28.65 (4.70)

    		95% CI28.22-29.2728.10-29.5827.89-29.41
    Waist circumference (cm).49

    		Mean (SD)103.98 (11.49)104.44 (11.91)103.46 (11.02)

    		95% CI102.59-105.38102.45-106.43101.50-105.42
    Cardiovascular risk factors, n (%)

    		Overweight127 (42.3)64 (42.7)63 (42.0).31

    		Obesity107 (35.7)52 (34.6)55 (36.7).31

    		High blood pressure204 (68.0)95 (63.3)109 (72.7).08

    		Diabetes131 (43.7)58 (38.7)73 (48.7).08

    		Dyslipidemia199 (66.3)100 (66.7)99 (66.0).90

    		Smoking107 (35.7)56 (37.3)51 (34.0).54

    		Former smoker116 (38.7)54 (36.0)62 (41.3).34
    Morbiditiesb63 (21.1)25 (16.8)38 (25.3).07
    Personal history of CVDc, n (%)

    		Stable angina48 (16.0)21 (14.0)27 (18.0).34

    		Unstable angina28 (9.3)10 (6.7)18 (12.1).11

    		NSTEMId27 (9.0)8 (5.3)19 (12.7).02

    		STEMIe37 (12.3)15 (10.0)22 (14.7).21

    		Arrhythmia17 (5.7)9 (6.0)8 (5.3).80

    		Stroke14 (4.7)9 (6.0)5 (3.3).27

    		Peripheral artery disease5 (1.7)3 (2.0)2 (1.3).65
    LVEFf (%).55g

    		Mean (SD)56.79 (10.41)56.79 (10.10)56.78 (10.74)

    		95% CI55.57-58.0055.12-58.4655.00-58.56
    Reason for catheterization, n (%).49

    		Stable angina108 (36.0)54 (36.0)54 (36.0)

    		Unstable angina45 (15.0)19 (12.7)26 (17.3)

    		NSTEMI59 (19.7)28 (18.7)31 (20.7)

    		STEMI88 (29.3)49 (32.7)39 (26.0)
    Stents, n.01h

    		Mean (SD)2.47 (1.67)2.26 (1.60)2.68 (1.70)

    		95% CI2.28-2.662.00-2.522.40-2.96
    Complete arterial revascularization, n (%)244 (81.6)125 (83.9)119 (79.3).30
    Discharge treatment, n (%)

    		Anticoagulants30 (10.0)18 (12.1)12 (8.0).24

    		Antiplatelets294 (98.3)146 (98.0)148 (98.7).64

    		Antihypertensives289 (96.7)140 (94.0)149 (99.3).01

    		Insulin43 (14.4)14 (9.4)29 (19.3).01

    		Oral antidiabetics149 (49.8)66 (44.3)83 (55.3).05

    		Statins280 (93.6)141 (94.6)139 (92.7).48

    amHealth: mobile health.

    bChronic obstructive pulmonary disease, kidney disease, and obstructive sleep apnea syndrome.

    cCVD: cardiovascular disease.

    dNSTEMI: non-ST-segment elevation myocardial infarction.

    eSTEMI: ST-segment elevation acute myocardial infarction.

    fLVEF: left ventricular ejection fraction.

    gMann-Whitney U test; median (IQR), mHealth vs control: 58.0 (64.75-52.00) vs 60.0 (65.00-54.00).

    hMann-Whitney U test; median (IQR), mHealth vs control: 2.00 (3.00-1.00) vs 2.00 (4.00-1.00).

    Outcome Variables

    Primary Outcomes

    The primary outcome variables are shown in Table 2. The score for adherence to the Mediterranean diet was significantly higher in the mHealth group than in the control group after both 3 months (mean 11.63, SD 1.70 points vs mean 9.32, SD 2.55 points; P<.001) and 6 months (mean 11.92, SD 1.70 points vs mean 8.92, SD 2.66 points; P<.001). The percentage of participants with good adherence to the Mediterranean diet (>9 points) was also significantly higher in the mHealth group than in the control group after 3 months (136/145, 93.8% vs 96/142, 67.6%; P<.001) and 6 months (135/143, 94.4% vs 85/141, 60.3%; P<.001).

    Regarding the frequency of eating food, the consumption of red meat was lower in the mHealth group than in the control group at 3 months (≤1 time/week: 142/145, 97.9% vs 107/142, 75.3%; P<.001) and 6 months (≤1 time/week: 141/143, 97.9% vs 96/141, 68.1%; P<.001). Moreover, the consumption of industrial pastries was lower in the mHealth group than in the control group at 3 months (<2 times/week: 128/145, 88.2% vs 89/142, 62.7%; P<.001) and 6 months (<2 times/week: 129/143, 89.6% vs 80/141, 56.8%; P<.001). In addition, the consumption of the following foods was significantly higher in the mHealth group than in the control group: oily fish (≥2 times/week: 116/145, 80.0% vs 68/142, 47.9%; P<.001 at 3 months and 124/143, 86.1% vs 64/141, 41.4%; P<.001 at 6 months), vegetables (≥2 times/day: 124/145, 85.5% vs 77/142, 54.2%; P<.001 at 3 months and 130/143, 90.3% vs 78/141, 55.3%; P<.001 at 6 months), fruit (≥2 times/day: 125/145, 86.2% vs 90/142, 63.4%; P<.001 at 3 months and 128/143, 88.9% vs 85/141, 60.2%; P<.001 at 6 months), and whole-meal cereals (≥1 time/day: 89/145, 61.3% vs 43/142, 30.2%; P<.001 at 3 months and 96/143, 66.7% vs 42/141, 29.8%; P<.001 at 6 months).

    Regarding the time spent doing PA each week (min/week), the mHealth group did significantly more PA than the control group at 3 months (mean 578.10, SD 326.14 min/week vs mean 443.46, SD 278.11 min/week; P<.001). Likewise, at 6 months, PA was higher in the mHealth group than in the control group (mean 614.51, SD 332.26 min/week vs mean 408.40, SD 274.49 min/week; P<.001). Regarding the intensity of PA (METs/week), the mHealth group performed more intense activity than the control group at 3 months (mean 1991.74, SD 1176.71 METs/week vs mean 1490.48, SD 925.89 METs/week; P<.001) and 6 months (mean 2112.66, SD 1196.67 METs/week vs mean 1372.60, SD 944.62 METs/week; P<.001). The PA was of moderate intensity in both groups.

    The control group had a significantly more sedentary lifestyle than the mHealth group (number of hours seated: mean 9.34, SD 2.13 vs mean 8.57, SD 1.89; P=.002 at 3 months and mean 9.59, SD 2.09 vs mean 8.38, SD 1.88; P<.001 at 6 months).

    Exercise capacity, assessed using the distance covered in meters during the 6-MWT, was significantly higher in the mHealth group than in the control group (mean 473.49, SD 102.28 meters vs mean 447.25, SD 93.68 meters; P=.04).

    Regarding smoking cessation, although more participants gave up smoking in the mHealth group than in the control group, the difference was not significant. However, the scores for nicotine dependence at 3 months decreased significantly in the mHealth group compared with the control group (mean 2.30, SD 2.27 points vs mean 4.14, SD 2.96 points; P=.03).

    The level of knowledge of CVRFs and a healthy lifestyle was significantly higher in the mHealth group than in the control group at both 3 months (mean 116.14, SD 4.23 points vs mean 111.02, SD 6.94 points; P<.001) and 6 months (mean 117.85, SD 3.83 points vs mean 111.00, SD 7.11 points; P<.001).

    Finally, the participants in the mHealth group expressed a high level of satisfaction with the app at 3 months (mean 42.32, SD 5.96 points) and 6 months (mean 42.53, SD 6.38 points), and rated it as excellent (>80.3 points) for usability at 3 months (mean 95.75, SD 4.04 points) and 6 months (mean 95.60, SD 4.03 points).

    Table 2. Primary outcome variables at baseline, and 3 and 6 months.
    VariableTotalMobile health groupControl groupP value
    Participants, n—a

    		Baseline300150150

    		3 months287145142

    		6 months284143141
    Mediterranean diet

    		Mediterranean diet adherence (score), mean (SD)


    		Baseline7.85 (2.52)7.78 (2.62)7.92 (2.42).48b


    		3 months10.48 (2.45)11.63 (1.70)9.32 (2.55)<.001b


    		6 months10.43 (2.69)11.92 (1.70)8.92 (2.66)<.001b

    		Good adherence, n (%)


    		Baseline117 (39.3)58 (38.7)60 (40.0).57


    		3 months232 (80.8)136 (93.8)96 (67.6)<.001


    		6 months200 (77.5)135 (94.4)85 (60.3)<.001
    Food consumption

    		Red meat ≤1/week, n (%)


    		Baseline127 (42.5)63 (42.3)64 (42.7).70


    		3 months249 (86.7)142 (97.9)107 (75.3)<.001


    		6 months237 (83.2)141 (97.9)96 (68.1)<.001

    		Blue fish/oily fish ≥2/week, n (%)


    		Baseline120 (40.0)60 (40.3)60 (40.0).57


    		3 months184 (64.1)116 (80.0)68 (47.9)<.001


    		6 months186 (66.0)124 (86.1)64 (45.4)<.001

    		Vegetables ≥2/day, n (%)


    		Baseline98 (32.7)49 (32.9)49 (32.6).86


    		3 months201 (70.0)124 (85.5)77 (54.2)<.001


    		6 months208 (73.0)130 (90.3)78 (55.3)<.001

    		Fruits ≥2/day, n (%)


    		Baseline145 (48.5)75 (50.4)70 (46.6).30


    		3 months215 (74.9)125 (86.2)90 (63.4)<.001


    		6 months213 (74.8)128 (88.9)85 (60.2)<.001

    		Whole grains ≥1/day, n (%)


    		Baseline76 (25.6)39 (26.4)37 (24.8).76


    		3 months132 (46.0)89 (61.3)43 (30.2)<.001


    		6 months138 (48.4)96 (66.7)42 (29.8)<.001

    		Industrial pastry <2/week, n (%)


    		Baseline134 (44.8)62 (41.7)72 (47.9).55


    		3 months217 (75.6)128 (88.2)89 (62.7)<.001


    		6 months209 (73.3)129 (89.6)80 (56.8)<.001
    Physical activity

    		IPAQc (min/week), mean (SD)


    		Baseline387.30 (342.72)389.81 (355.78)384.80 (330.33).87b


    		3 months511.49 (310.22)578.10 (326.14)443.46 (278.11)<.001b


    		6 months512.18 (321.44)614.51 (332.26)408.40 (274.49)<.001b

    		IPAQ (METsd/week), mean (SD)


    		Baseline1411.48 (1480.98)1457.28 (1632.15)1365.68 (1316.49).89b


    		3 months1743.73 (1087.58)1991.74 (1176.71)1490.48 (925.89)<.001b


    		6 months1745.24 (1139.02)2112.66 (1196.67)1372.60 (944.62)<.001b

    		IPAQ H (sitting/week), mean (SD)


    		Baseline9.64 (2.40)9.58 (2.44)9.69 (2.37).84b


    		3 months8.95 (2.04)8.57 (1.89)9.34 (2.13).002b


    		6 months8.98 (2.07)8.38 (1.88)9.59 (2.09)<.001b

    		6-MWTe (meters), mean (SD)


    		6 months460.75 (98.87)473.49 (102.28)447.25 (93.68).04
    Tobacco

    		Smokers, n (%)


    		Baseline107 (35.7)56 (37.3)51 (34.0).54


    		3 months42 (42.0)20 (37.7)22 (46.8).35


    		6 months42 (43.8)17 (34.7)25 (53.2).06

    		Smoking cessation, n (%)


    		3 months58 (58.0)33 (62.3)25 (53.2).35


    		6 months54 (56.3)32 (65.3)22 (46.8).06

    		Nicotine dependence (Fagerström score), mean (SD)


    		Baseline5.32 (2.77)5.39 (2.93)5.24 (2.62).77


    		3 months3.26 (2.78)2.30 (2.27)4.14 (2.96).03


    		6 months3.05 (2.84)2.18 (2.37)3.64 (3.02).10
    Cardiovascular risk factors

    		CVRFfknowledge (score), mean (SD)


    		Baseline108.26 (9.34)108.15 (7.39)108.37 (10.97).40b


    		3 months113.61 (6.27)116.14 (4.23)111.02 (6.94)<.001b


    		6 months114.45 (6.64)117.85 (3.83)111.00 (7.11)<.001b
    App satisfaction (score), mean (SD)—


    		3 months—42.32 (5.96)—


    		6 months—42.53 (6.38)—
    App usability (score), mean (SD)—


    		3 months—95.75 (4.04)—


    		6 months—95.60 (4.03)—

    aNot applicable.

    bMann-Whitney U test.

    cIPAQ: International Physical Activity Questionnaire.

    dMET: metabolic equivalent.

    e6-MWT: 6-minute walk test.

    fCVRF: cardiovascular risk factor.

    Secondary Outcomes

    The secondary outcome variables are shown in Multimedia Appendix 2. The anthropometric variables (BMI and WC) improved slightly in both groups, with no significant differences between the groups.

    SBP was significantly lower in the mHealth group than in the control group at both 3 months (mean 128.96, SD 15.87 mmHg vs mean 133.27, SD 14.85 mmHg; P=.01) and 6 months (mean 130.00, SD 21.90 mmHg vs mean 135.78, SD 16.73 mmHg; P=.01). However, no significant differences were found in DBP between the groups. HR was significantly lower in the mHealth group than in the control group at 3 months (mean 66.75, SD 8.91 beats/min vs mean 71.93, SD 9.86 beats/min; P<.001) but not at 6 months.

    The levels of lipid variables (TC, HDL-C, LDL-C, and triglycerides) showed large decreases in both groups, with no significant differences between the groups.

    Blood sugar levels were significantly lower in the mHealth group than in the control group at 6 months (mean 101.10, SD 18.57 mg/dL vs mean 115.44, SD 39.46 mg/dL; P=.007). However, improvements were not reflected in the HbA1c value.


    Principal Findings

    This clinical trial evaluated the efficacy of an mHealth intervention based on the eMOTIVA app with regard to secondary prevention outcomes in patients who experienced ACS. The following variables were assessed: improvements in lifestyle (adherence to the Mediterranean diet, frequency of consumption of foods, PA, exercise capacity, sedentary time, smoking cessation, and level of knowledge) and control of CVRFs (BMI, WC, blood pressure, HR, TC, LDL-C, HDL-C, triglycerides, blood sugar, and HbA1c). Our results showed that the eMOTIVA app achieved significantly more favorable results in the intervention group compared with the control group in terms of adherence to the Mediterranean diet, frequency of consumption of foods, time and intensity of PA, sedentary time and exercise capacity, level of knowledge about CVRFs, SBP, HR, and blood sugar. Moreover, the participants reported being very satisfied with the app, and they rated its usability as excellent.

    Primary Outcome Variables

    Healthy Diet

    A healthy diet plays a very important role in both the prevention and treatment of CAD. Strong evidence exists about the efficacy of the Mediterranean diet for managing CVRFs for secondary prevention in patients [34,35]. In our trial, adherence to the Mediterranean diet increased significantly in the mHealth group compared with the control group at both 3 and 6 months. Moreover, in the mHealth group, an increase was observed in the consumption of healthy foods, such as fruits, vegetables, whole-meal cereals, and oily fish, and a decrease was observed in the consumption of red meats and industrial pastries. In a previous study that analyzed a cardiac telerehabilitation program with a mobile care monitoring strategy after ACS, significant improvements were noted in adherence to the Mediterranean diet in the intervention group [36]. By contrast, other authors have not reported significant differences between groups for healthy eating with the use of a support program based on text messages for patients with CAD, type 2 diabetes, or both [37]. Given our results, mHealth technology involving an app may be useful for improving eating behavior and maintaining a healthy diet in these patients compared with interventions based on text messages alone. The clinical benefits of these improvements in diet have been reported. For example, studies have stated that eating fish that is rich in omega-3 polyunsaturated fatty acids, such as oily fish, at least once a week is associated with a 16% decrease in the risk of cardiovascular disease [38]. Likewise, an increase in fiber consumption of 7 g/day is associated with a 9% decrease in the risk of cardiovascular disease [39].

    Overall PA

    PA is a modifiable factor that plays a crucial role in decreasing recurrent coronary events and mortality. The cardiovascular benefits of PA are well known, with recent meta-analyses reporting that it is significantly associated with a decrease in cardiovascular and all-cause mortality in patients with CAD [40-42]. Our results are promising because participants who used the eMOTIVA app performed more PA and were less sedentary. Although PA was self-reported in our trial, an objective test was conducted to measure exercise capacity using the 6-MWT, and participants in the mHealth group were found to have significantly better exercise capacity. Our results are in line with those obtained in other trials in which the effectiveness of mHealth in CAD patients was analyzed [43-46]. Recent meta-analyses have revealed that the use of interactive mobile apps with self-recording and feedback can achieve an increase in the amount of PA performed by participants and an improvement in their functional capacity [15,47].

    Tobacco Use

    Stopping smoking is one of the most effective secondary prevention measures after experiencing ACS [48]. The EUROASPIRE study [49], which assessed smoking cessation rates in patients with CAD in the whole of Europe and had a follow-up of 2-10 years, stated that individuals who stopped smoking showed a reduction in general mortality of nearly 50%. In our study, although no differences were observed between the groups regarding smoking cessation, nicotine dependence after 3 months, measured by the Fagerström test, was significantly lower in the mHealth group than in the control group. A recent meta-analysis [48] that analyzed smoking cessation and risk factors to continue smoking after ACS concluded that the smoking cessation rate after ACS was 45%. These results are similar to our findings, where we observed that 46.8% (22/51) of participants in the control group stopped smoking, while this figure was higher in the mHealth group (32/56, 65.3%), suggesting that our interactive tool helped participants to maintain the willpower to change, possibly owing to the support and motivation they perceived. Another recent meta-analysis [50] found that telehealth interventions had a significant effect on smoking cessation in patients with CAD. By contrast, other meta-analyses did not find significant differences in smoking cessation between groups using telehealth interventions, but these interventions did not use interactive tools with recording, feedback, or gamification [47,51,52].

    Knowledge of CVRFs

    The level of knowledge of CVRFs and a healthy lifestyle in patients is not adequately addressed in trials analyzing the efficacy of mHealth. In our study, the level of knowledge was significantly higher in the mHealth group than in the control group. These results are in line with those obtained by other authors who reported that the use of a social media platform with learning modules significantly increased the knowledge and awareness of CAD [43]. Therefore, interactive and innovative mHealth tools can play a part in increasing the knowledge of a healthy lifestyle. In our study, the virtual classroom incorporated in the app may have been responsible for the observed increase in knowledge.

    Secondary Outcome Variables

    BMI and WC

    A recent meta-analysis that analyzed the efficacy of mHealth for decreasing risk factors related to CAD found significant decreases in both BMI and WC in the intervention group [16]. However, other recent meta-analyses have reported no significant reductions in these anthropometric values with the use of an app [15,47,51,52], which is in agreement with our results. The participants in the mHealth group in our study consumed more vegetables, fruits, whole-meal cereals, and fish, and less red meat and industrial pastries. Moreover, they complied with the recommendation to perform at least 150 minutes of PA per week. Our application, however, was not specifically designed with weight loss in mind, although it did include dietary advice, and losing weight is known to involve more than merely eating healthy food. It is also necessary to limit calorie intake and increase energy expenditure through PA [53].

    Blood Pressure and HR

    In our study, SBP was significantly lower in the mHealth group than in the control group. Our results are in agreement with the results of other studies that analyzed the use of health care apps in patients with CAD [43,54,55]. This clinical benefit is of note because a meta-analysis [56] concluded that a 10-mmHg decrease in SBP reduces the risks of major cardiovascular events by approximately 20%, CAD by 17%, and all-cause mortality by 13%. However, no significant improvements were found in DBP, possibly due to the intensive drug treatment prescribed after a coronary event that had similar effects on patients in both the mHealth and control groups. On the other hand, the significant decrease in SBP found in our study could be explained by greater compliance with antihypertensive treatment among participants using the app or by greater adherence to the Mediterranean diet and an increase in PA. The recent prevention guidelines for cardiovascular diseases state that lifestyle interventions involving a healthy diet and physical exercise among patients with high blood pressure may be enough to control blood readings and even reduce the amount of medication required to control them [57]. Regarding HR, several trials found that mobile technology did not result in significant differences between groups [24,46,58]. By contrast, Dorje et al [43] reported a significant decrease in HR after 6 months through the use of a WeChat platform. In our study, decreases in HR to below 70 beats/min were found after both 3 and 6 months in the intervention group, but only the decrease at 3 months was significant. The higher HR decrease in the mHealth group compared with the control group may be because the mHealth group performed more PA, which has been shown to be related to a decrease in resting HR [59]. Increases in HR have a direct correlation with cardiovascular events. Several kinds of medications, including beta blockers, have been shown to help with the treatment aim of reducing HR in patients with CAD. Thus, an HR below 80 beats/min and close to 70 beats/min is a treatment goal in hypertensive patients with CAD [60].

    Lipids, HbA1c, and Blood Sugar Values

    Keeping blood lipid levels under control is a very important aim in the secondary prevention of cardiovascular diseases [54]. A meta-analysis conducted by Cholesterol Treatment Trialists’ Collaboration [61] reported that the risk of major vascular events decreased by 21% for each 1 mmol/L reduction in LDL-C achieved with statin treatment. In our study, as in other clinical trials on the efficacy of mHealth in patients with coronary disease, blood lipid values decreased drastically, but no significant differences were found between the groups due to the powerful drug treatment received by all patients after a coronary event [37,46,62]. Likewise, a high blood sugar level is also an important risk factor that can lead to the onset and development of CAD. Diabetes mellitus is an important risk factor for AMI and a common comorbidity among patients hospitalized with AMI (present in approximately 30% of cases) [63]. Our study did not find a significant decrease in HbA1c. However, blood sugar levels decreased significantly in the mHealth group after 6 months. These findings for HbA1c may also be a result of the intensive drug treatment followed by the patients in both the mHealth and control groups.

    Satisfaction and Usability

    High levels of satisfaction and acceptance of the health care received have been observed to have positive implications for health outcomes and the patient’s experience, thereby reducing health care costs and the use of emergency services [64]. In our study, satisfaction after 6 months of using the app reached a mean of 42.53 (SD 6.38) points out of 50 points, which was considered a high level of satisfaction, while the score for usability reached a mean of 95.60 (SD 4.03) points out of 100 points, which was considered to be excellent. The self-recording of PA, diet, and clinical variables along with positive personalized feedback likely contributed to the high level of satisfaction and usability reported by the participants who used the eMOTIVA app. Other studies that have used mHealth interventions with these patients have also reported high levels of usability of 80.4 points out of 100 [36] and 87.3 points out of 100 [65]. These findings highlight the potential of mHealth apps as useful tools for improving recovery and supporting secondary prevention after a coronary event. They are particularly relevant for populations in which access to a medical center to take part in CR is difficult, either due to living in remote areas or economic reasons.

    Limitations

    This study has some limitations. First, one of the inclusion criteria was that patients had to have a smartphone. However, the ever-increasing use of these devices in the lives of people globally suggests that this limitation is of little importance. Due to the nature of the study, as in most trials with digital tools, it was impossible for either the patients or health care staff to be blinded. However, the staff analyzing the data were indeed blinded to the group allocation of each participant. Some variables were self-reported by patients (adherence to the Mediterranean diet and PA), which could have resulted in them overestimating their health-promoting behavior. However, the results were confirmed by other variables that were measured by health care professionals, such as exercise capacity assessed using the 6-MWT and blood pressure. Another possible limitation is that patients in the control group were 2 years older than patients in the mHealth group, and the proportion of patients receiving insulin, oral antidiabetics, and antihypertensives was slightly higher in the control group.

    Strengths

    A strength of the study that stands out is the relatively high number of participants included considering that this was a voluntary intervention study using mHealth, and there were very few dropouts. This might imply that the app was easy to use and that the patients were motivated to change their habits. The use of validated questionnaires specific to this population is another strength. In addition, the hospital where the intervention was conducted is a public reference hospital that treats patients from urban and rural areas. Thus, the sample is representative for the generalization of the results. Finally, the educational sessions and app were designed taking into consideration validated psychological theories. Likewise, our eMOTIVA app included setting objectives, self-monitoring of diet and PA, feedback, and gamification, which are resources that have been shown to improve the results obtained with these mHealth tools [36].

    Conclusions

    With the use of the eMOTIVA app, favorable results were obtained in the mHealth group compared with the control group in terms of adherence to the Mediterranean diet, frequency of eating certain foods, PA, sedentary time, exercise capacity, level of knowledge of CVRFs, SBP, HR, and blood sugar levels. This trial highlights the potential of mHealth as a complementary or alternative approach to CR programs conducted in medical centers, which are often overburdened. In addition, the participants reported high levels of satisfaction with the app, and it presented excellent usability. Thus, it could be a promising new tool for the CR of patients with CAD in general and for patients who have difficulty attending a health center or hospital in particular.

    Acknowledgments

    A subsidy was received for the financing of Research and Biomedical Innovation in Health Sciences within the framework of the Integrated Territorial Initiative 2014-2020 for the province of Cádiz. The project was 80% co-financed by the European Union within the framework of the FEDER (European Regional Development Fund) Andalusia Operational Program 2014-2020 and Ministry of Health and Consumption, Junta de Andalucía (reference code: PI-0014-2019). JAT is funded by CIBEROBN (Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición; CB12/03/30038)-Instituto de Salud Carlos III, IUNICS (Instituto Universitario de Investigación en Ciencias de la Salud), IDISBA (Fundación Instituto de Investigación Sanitaria Islas Baleares) and co-funded by the European Regional Development Fund.

    Conflicts of Interest

    None declared.

    Multimedia Appendix 1

    CONSORT e-HEALTH checklist (V 1.6.1).

    PDF File (Adobe PDF File), 1111 KB
    Multimedia Appendix 2

    Secondary outcome variables at baseline, and 3 and 6 months.

    PDF File (Adobe PDF File), 112 KB
    1. Enfermedades cardiovasculares. World Health Organization. URL: https://www.who.int/es/health-topics/cardiovascular-dise ases#tab=tab_1 [accessed 2023-04-19]
    2. Ferreira-González I. Epidemiología de la enfermedad coronaria. Revista Española de Cardiología. Feb 2014;67(2):139-144. [CrossRef]
    3. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. Oct 17, 2020;396(10258):1204-1222. [FREE Full text] [CrossRef] [Medline]
    4. Hasbani NR, Ligthart S, Brown MR, Heath AS, Bebo A, Ashley KE, et al. American Heart Association’s life’s simple 7: lifestyle recommendations, polygenic risk, and lifetime risk of coronary heart disease. Circulation. Mar 15, 2022;145(11):808-818. [CrossRef]
    5. Estadística de Defunciones según la Causa de Muerte-Última Nota de prensa. Instituto Nacional de Estadística. URL: https:/​/www.​ine.es/​dyngs/​INEbase/​es/​operacion.​htm?c=Estadistica_C&cid=1254736176780&menu=ultiDatos&idp=1254735573175 [accessed 2024-03-17]
    6. Bae J, Woo S, Lee J, Park S, Kwon SW, Choi SH, et al. mHealth interventions for lifestyle and risk factor modification in coronary heart disease: randomized controlled trial. JMIR Mhealth Uhealth. Sep 24, 2021;9(9):e29928. [FREE Full text] [CrossRef] [Medline]
    7. Chow CK, Ariyarathna N, Islam SMS, Thiagalingam A, Redfern J. mHealth in cardiovascular health care. Heart Lung Circ. Aug 2016;25(8):802-807. [CrossRef] [Medline]
    8. Lu C. Analysis of the effectiveness of multi-disciplinary team integrated management combined with full-media health education intervention in patients with coronary heart disease and diabetes mellitus. Biotechnol Genet Eng Rev. Apr 17, 2023:1-15. [CrossRef] [Medline]
    9. Liu X, Shi Y, Willis K, Wu C, Johnson M. Health education for patients with acute coronary syndrome and type 2 diabetes mellitus: an umbrella review of systematic reviews and meta-analyses. BMJ Open. Oct 16, 2017;7(10):e016857. [FREE Full text] [CrossRef] [Medline]
    10. Rathod KS, Comer K, Casey-Gillman O, Moore L, Mills G, Ferguson G, et al. Early hospital discharge following PCI for patients with STEMI. J Am Coll Cardiol. Dec 21, 2021;78(25):2550-2560. [FREE Full text] [CrossRef] [Medline]
    11. Piepoli MF, Corrà U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. European Journal of Cardiovascular Prevention & Rehabilitation. Feb 2010;17(1):1-17. [CrossRef]
    12. McDonagh ST, Dalal H, Moore S, Clark CE, Dean SG, Jolly K, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. Oct 27, 2023;10(10):CD007130. [CrossRef] [Medline]
    13. Aljedaani B, Babar MA. Challenges with developing secure mobile health applications: systematic review. JMIR Mhealth Uhealth. Jun 21, 2021;9(6):e15654. [FREE Full text] [CrossRef] [Medline]
    14. Palmer MJ, Barnard S, Perel P, Free C. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. Cochrane Database Syst Rev. Jun 22, 2018;6(6):CD012675. [FREE Full text] [CrossRef] [Medline]
    15. Cruz-Cobo C, Bernal-Jiménez MÁ, Vázquez-García R, Santi-Cano MJ. Effectiveness of mHealth interventions in the control of lifestyle and cardiovascular risk factors in patients after a coronary event: systematic review and meta-analysis. JMIR Mhealth Uhealth. Dec 02, 2022;10(12):e39593. [FREE Full text] [CrossRef] [Medline]
    16. Xu Y, Ye H, Zhu Y, Du S, Xu G, Wang Q. The efficacy of mobile health in alleviating risk factors related to the occurrence and development of coronary heart disease: A systematic review and meta-analysis. Clin Cardiol. May 16, 2021;44(5):609-619. [FREE Full text] [CrossRef] [Medline]
    17. Eysenbach G, CONSORT-EHEALTH Group. CONSORT-EHEALTH: improving and standardizing evaluation reports of Web-based and mobile health interventions. J Med Internet Res. Dec 31, 2011;13(4):e126. [FREE Full text] [CrossRef] [Medline]
    18. Cruz-Cobo C, Bernal-Jiménez MÁ, Calle-Pérez G, Gheorghe L, Gutiérrez-Barrios A, Cañadas-Pruaño D, et al. Impact of mHealth application on adherence to cardiac rehabilitation guidelines after a coronary event: Randomised controlled clinical trial protocol. Digit Health. Mar 19, 2024;10:20552076241234474. [FREE Full text] [CrossRef] [Medline]
    19. Cohen J. A power primer. Psychol Bull. Jul 1992;112(1):155-159. [CrossRef] [Medline]
    20. Martínez-González MA, García-Arellano A, Toledo E, Salas-Salvadó J, Buil-Cosiales P, Corella D, et al. PREDIMED Study Investigators. A 14-item Mediterranean diet assessment tool and obesity indexes among high-risk subjects: the PREDIMED trial. PLoS One. 2012;7(8):e43134. [FREE Full text] [CrossRef] [Medline]
    21. Elosua R, Marrugat J, Molina L, Pons S, Pujol E. Validation of the Minnesota leisure time physical activity questionnaire in Spanish men. The MARATHOM investigators. Am J Epidemiol. Jun 15, 1994;139(12):1197-1209. [CrossRef] [Medline]
    22. Elosua R, Garcia M, Aguilar A, Molina L, Covas MI, Marrugat J. Validation of the Minnesota leisure time physical activity questionnaire in Spanish women: investigators of the MARATDON group. Med Sci Sports Exerc. Aug 2000;32(8):1431-1437. [CrossRef] [Medline]
    23. Sardi L, Idri A, Fernández-Alemán JL. A systematic review of gamification in e-Health. J Biomed Inform. Jul 2017;71:31-48. [FREE Full text] [CrossRef] [Medline]
    24. Gallagher R, Chow C, Parker H, Neubeck L, Celermajer D, Redfern J, et al. The effect of a game-based mobile app 'MyHeartMate' to promote lifestyle change in coronary disease patients: a randomized controlled trial. Eur Heart J Digit Health. Jan 2023;4(1):33-42. [FREE Full text] [CrossRef] [Medline]
    25. Xu L, Li J, Zhang X, Pang Y, Yu T, Lian X, et al. Mobile health-based gamification intervention to increase physical activity participation among patients with coronary heart disease: study protocol of a randomised controlled trial. BMJ Open. Jan 31, 2022;12(1):e054623. [FREE Full text] [CrossRef] [Medline]
    26. Fernández-Ballart JD, Piñol JL, Zazpe I, Corella D, Carrasco P, Toledo E, et al. Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain. Br J Nutr. Jun 2010;103(12):1808-1816. [CrossRef] [Medline]
    27. Román Viñas B, Ribas Barba L, Ngo J, Serra Majem L. [Validity of the international physical activity questionnaire in the Catalan population (Spain)]. Gac Sanit. 2013;27(3):254-257. [FREE Full text] [CrossRef] [Medline]
    28. Bellet RN, Adams L, Morris NR. The 6-minute walk test in outpatient cardiac rehabilitation: validity, reliability and responsiveness--a systematic review. Physiotherapy. Dec 2012;98(4):277-286. [CrossRef] [Medline]
    29. González MN, Rodríguez NM. Prueba de la marcha de los 6 minutos. Medicina Respiratoria. 2016;9(1):15-22. [FREE Full text]
    30. Hamilton DM, Haennel RG. Validity and reliability of the 6-minute walk test in a cardiac rehabilitation population. J Cardiopulm Rehabil. 2000;20(3):156-164. [CrossRef] [Medline]
    31. Sharma MK, Suman LN, Srivastava K, Suma N, Vishwakarma A. Psychometric properties of Fagerstrom Test of Nicotine Dependence: A systematic review. Ind Psychiatry J. 2021;30(2):207-216. [FREE Full text] [CrossRef] [Medline]
    32. Bernal-Jiménez MÁ, Calle-Pérez G, Gutiérrez-Barrios A, Gheorghe L, Solano-Mulero AM, Trujillo-Garrido N, et al. Design and validation of a scale of knowledge of cardiovascular risk factors and lifestyle after coronary event. J Clin Med. May 14, 2022;11(10):2773. [FREE Full text] [CrossRef] [Medline]
    33. Hyzy M, Bond R, Mulvenna M, Bai L, Dix A, Leigh S, et al. System usability scale benchmarking for digital health apps: meta-analysis. JMIR Mhealth Uhealth. Aug 18, 2022;10(8):e37290. [FREE Full text] [CrossRef] [Medline]
    34. Quintana-Navarro GM, Alcala-Diaz JF, Lopez-Moreno J, Perez-Corral I, Leon-Acuña A, Torres-Peña JD, et al. Long-term dietary adherence and changes in dietary intake in coronary patients after intervention with a Mediterranean diet or a low-fat diet: the CORDIOPREV randomized trial. Eur J Nutr. Aug 2020;59(5):2099-2110. [CrossRef] [Medline]
    35. Laffond A, Rivera-Picón C, Rodríguez-Muñoz PM, Juárez-Vela R, Ruiz de Viñaspre-Hernández R, Navas-Echazarreta N, et al. Mediterranean diet for primary and secondary prevention of cardiovascular disease and mortality: an updated systematic review. Nutrients. Jul 28, 2023;15(15):3356. [FREE Full text] [CrossRef] [Medline]
    36. Dalli Peydró E, Sanz Sevilla N, Tuzón Segarra MT, Miró Palau V, Sánchez Torrijos J, Cosín Sales J. A randomized controlled clinical trial of cardiac telerehabilitation with a prolonged mobile care monitoring strategy after an acute coronary syndrome. Clin Cardiol. Jan 24, 2022;45(1):31-41. [FREE Full text] [CrossRef] [Medline]
    37. Cheung NW, Redfern J, Thiagalingam A, Hng T, Marschner S, Haider R, et al. SupportMe Investigators. Effect of mobile phone text messaging self-management support for patients with diabetes or coronary heart disease in a chronic disease management program (SupportMe) on blood pressure: pragmatic randomized controlled trial. J Med Internet Res. Jun 16, 2023;25:e38275. [FREE Full text] [CrossRef] [Medline]
    38. Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr. Apr 2012;15(4):725-737. [CrossRef] [Medline]
    39. Threapleton DE, Greenwood DC, Evans CEL, Cleghorn CL, Nykjaer C, Woodhead C, et al. Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. BMJ. Dec 19, 2013;347(dec19 2):f6879-f6879. [FREE Full text] [CrossRef] [Medline]
    40. Claes J, Buys R, Budts W, Smart N, Cornelissen VA. Longer-term effects of home-based exercise interventions on exercise capacity and physical activity in coronary artery disease patients: A systematic review and meta-analysis. Eur J Prev Cardiol. Feb 2017;24(3):244-256. [CrossRef] [Medline]
    41. Cheng W, Zhang Z, Cheng W, Yang C, Diao L, Liu W. Associations of leisure-time physical activity with cardiovascular mortality: A systematic review and meta-analysis of 44 prospective cohort studies. Eur J Prev Cardiol. Nov 30, 2018;25(17):1864-1872. [CrossRef] [Medline]
    42. Cleven L, Krell-Roesch J, Nigg CR, Woll A. The association between physical activity with incident obesity, coronary heart disease, diabetes and hypertension in adults: a systematic review of longitudinal studies published after 2012. BMC Public Health. May 19, 2020;20(1):726. [FREE Full text] [CrossRef] [Medline]
    43. Dorje T, Zhao G, Tso K, Wang J, Chen Y, Tsokey L, et al. Smartphone and social media-based cardiac rehabilitation and secondary prevention in China (SMART-CR/SP): a parallel-group, single-blind, randomised controlled trial. Lancet Digit Health. Nov 2019;1(7):e363-e374. [FREE Full text] [CrossRef] [Medline]
    44. Fang J, Huang B, Xu D, Li J, Au WW. Innovative application of a home-based and remote sensing cardiac rehabilitation protocol in Chinese patients after percutaneous coronary intervention. Telemed J E Health. Apr 2019;25(4):288-293. [CrossRef] [Medline]
    45. Piotrowicz E, Pencina MJ, Opolski G, Zareba W, Banach M, Kowalik I, et al. Effects of a 9-week hybrid comprehensive telerehabilitation program on long-term outcomes in patients with heart failure: the telerehabilitation in heart failure patients (TELEREH-HF) randomized clinical trial. JAMA Cardiol. Mar 01, 2020;5(3):300-308. [FREE Full text] [CrossRef] [Medline]
    46. Yudi MB, Clark DJ, Tsang D, Jelinek M, Kalten K, Joshi S, et al. SMARTphone-based, early cardiac REHABilitation in patients with acute coronary syndromes: a randomized controlled trial. Coron Artery Dis. Aug 01, 2021;32(5):432-440. [CrossRef] [Medline]
    47. Ramachandran HJ, Jiang Y, Tam WWS, Yeo TJ, Wang W. Effectiveness of home-based cardiac telerehabilitation as an alternative to Phase 2 cardiac rehabilitation of coronary heart disease: a systematic review and meta-analysis. Eur J Prev Cardiol. May 25, 2022;29(7):1017-1043. [FREE Full text] [CrossRef] [Medline]
    48. Lovatt S, Wong CW, Holroyd E, Butler R, Phan T, Patwala A, et al. Smoking cessation after acute coronary syndrome: A systematic review and meta-analysis. Int J Clin Pract. Dec 2021;75(12):e14894. [CrossRef] [Medline]
    49. Snaterse M, Deckers JW, Lenzen MJ, Jorstad HT, De Bacquer D, Peters RJG, et al. EUROASPIRE Investigators. Smoking cessation in European patients with coronary heart disease. Results from the EUROASPIRE IV survey: A registry from the European Society of Cardiology. Int J Cardiol. May 01, 2018;258:1-6. [FREE Full text] [CrossRef] [Medline]
    50. Turan Kavradim S, Özer Z, Boz İ. Effectiveness of telehealth interventions as a part of secondary prevention in coronary artery disease: a systematic review and meta-analysis. Scand J Caring Sci. Sep 20, 2020;34(3):585-603. [CrossRef] [Medline]
    51. Huang K, Liu W, He D, Huang B, Xiao D, Peng Y, et al. Telehealth interventions versus center-based cardiac rehabilitation of coronary artery disease: A systematic review and meta-analysis. Eur J Prev Cardiol. Aug 2015;22(8):959-971. [CrossRef] [Medline]
    52. Jin K, Khonsari S, Gallagher R, Gallagher P, Clark AM, Freedman B, et al. Telehealth interventions for the secondary prevention of coronary heart disease: A systematic review and meta-analysis. Eur J Cardiovasc Nurs. Apr 2019;18(4):260-271. [CrossRef] [Medline]
    53. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. Sep 10, 2019;140(11):e596-e646. [FREE Full text] [CrossRef] [Medline]
    54. Skobel E, Knackstedt C, Martinez-Romero A, Salvi D, Vera-Munoz C, Napp A, et al. Internet-based training of coronary artery patients: the Heart Cycle Trial. Heart Vessels. Apr 2017;32(4):408-418. [FREE Full text] [CrossRef] [Medline]
    55. Li Y, Gong Y, Zheng B, Fan F, Yi T, Zheng Y, et al. Effects on adherence to a mobile app-based self-management digital therapeutics among patients with coronary heart disease: pilot randomized controlled trial. JMIR Mhealth Uhealth. Feb 15, 2022;10(2):e32251. [FREE Full text] [CrossRef] [Medline]
    56. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. Mar 05, 2016;387(10022):957-967. [CrossRef] [Medline]
    57. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J. Aug 01, 2016;37(29):2315-2381. [FREE Full text] [CrossRef] [Medline]
    58. Lunde P, Bye A, Bergland A, Grimsmo J, Jarstad E, Nilsson BB. Long-term follow-up with a smartphone application improves exercise capacity post cardiac rehabilitation: A randomized controlled trial. Eur J Prev Cardiol. Nov 2020;27(16):1782-1792. [FREE Full text] [CrossRef] [Medline]
    59. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, ESC National Cardiac Societies, et al. ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. Sep 07, 2021;42(34):3227-3337. [CrossRef] [Medline]
    60. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. Dec 01, 2023;41(12):1874-2071. [CrossRef] [Medline]
    61. Sniderman A, Thanassoulis G, Couture P, Williams K, Alam A, Furberg CD. Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering. J Clin Lipidol. 2012;6(4):303-309. [CrossRef] [Medline]
    62. Widmer RJ, Allison TG, Lennon R, Lopez-Jimenez F, Lerman LO, Lerman A. Digital health intervention during cardiac rehabilitation: A randomized controlled trial. Am Heart J. Jun 2017;188:65-72. [CrossRef] [Medline]
    63. Milazzo V, Cosentino N, Genovese S, Campodonico J, Mazza M, De Metrio M, et al. Diabetes mellitus and acute myocardial infarction: impact on short and long-term mortality. Adv Exp Med Biol. 2021;1307:153-169. [CrossRef] [Medline]
    64. Hibbard JH, Greene J, Overton V. Patients with lower activation associated with higher costs; delivery systems should know their patients' 'scores'. Health Aff (Millwood). Feb 2013;32(2):216-222. [CrossRef] [Medline]
    65. Johnston N, Bodegard J, Jerström S, Åkesson J, Brorsson H, Alfredsson J, et al. Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: A randomized study. Am Heart J. Aug 2016;178:85-94. [FREE Full text] [CrossRef] [Medline]

    ‎
    6-MWT: 6-minute walk test
    ACS: acute coronary syndrome
    AMI: acute myocardial infarction
    CAD: coronary artery disease
    CR: cardiac rehabilitation
    CVRF: cardiovascular risk factor
    DBP: diastolic blood pressure
    HDL-C: high-density lipoprotein cholesterol
    HR: heart rate
    LDL-C: low-density lipoprotein cholesterol
    MET: metabolic equivalent
    PA: physical activity
    PCI: percutaneous coronary intervention
    SBP: systolic blood pressure
    TC: total cholesterol
    WC: waist circumference

    Edited by L Buis; submitted 13.12.23; peer-reviewed by NJ Haque, TAR Sure, S Lopes; comments to author 01.04.24; revised version received 17.04.24; accepted 28.05.24; published 25.07.24.

    Copyright

    ©Celia Cruz-Cobo, María Ángeles Bernal-Jiménez, Germán Calle, Livia Luciana Gheorghe, Alejandro Gutiérrez-Barrios, Dolores Cañadas, Josep A Tur, Rafael Vázquez-García, María José Santi-Cano. Originally published in JMIR mHealth and uHealth (https://mhealth.jmir.org), 25.07.2024.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR mHealth and uHealth, is properly cited. The complete bibliographic information, a link to the original publication on https://mhealth.jmir.org/, as well as this copyright and license information must be included.